1. Home
  2. KPTI vs HLVX Comparison

KPTI vs HLVX Comparison

Compare KPTI & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • HLVX
  • Stock Information
  • Founded
  • KPTI 2008
  • HLVX 2020
  • Country
  • KPTI United States
  • HLVX United States
  • Employees
  • KPTI N/A
  • HLVX N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • HLVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • KPTI Health Care
  • HLVX Health Care
  • Exchange
  • KPTI Nasdaq
  • HLVX Nasdaq
  • Market Cap
  • KPTI 81.1M
  • HLVX 92.9M
  • IPO Year
  • KPTI 2013
  • HLVX 2022
  • Fundamental
  • Price
  • KPTI $0.62
  • HLVX $1.86
  • Analyst Decision
  • KPTI Strong Buy
  • HLVX Hold
  • Analyst Count
  • KPTI 4
  • HLVX 5
  • Target Price
  • KPTI $5.00
  • HLVX $2.33
  • AVG Volume (30 Days)
  • KPTI 768.4K
  • HLVX 169.4K
  • Earning Date
  • KPTI 02-19-2025
  • HLVX 03-19-2025
  • Dividend Yield
  • KPTI N/A
  • HLVX N/A
  • EPS Growth
  • KPTI N/A
  • HLVX N/A
  • EPS
  • KPTI N/A
  • HLVX N/A
  • Revenue
  • KPTI $148,442,000.00
  • HLVX N/A
  • Revenue This Year
  • KPTI $4.47
  • HLVX N/A
  • Revenue Next Year
  • KPTI $7.35
  • HLVX N/A
  • P/E Ratio
  • KPTI N/A
  • HLVX N/A
  • Revenue Growth
  • KPTI 1.77
  • HLVX N/A
  • 52 Week Low
  • KPTI $0.58
  • HLVX $1.55
  • 52 Week High
  • KPTI $1.70
  • HLVX $20.22
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 43.29
  • HLVX 45.95
  • Support Level
  • KPTI $0.58
  • HLVX $1.67
  • Resistance Level
  • KPTI $0.67
  • HLVX $1.97
  • Average True Range (ATR)
  • KPTI 0.05
  • HLVX 0.08
  • MACD
  • KPTI -0.00
  • HLVX -0.01
  • Stochastic Oscillator
  • KPTI 31.02
  • HLVX 51.91

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About HLVX HilleVax Inc.

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Share on Social Networks: